Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report
- Collection:
-
Health Policy and Services Research
- Contributor(s):
-
Institute for Clinical and Economic Review, issuing body.
Midwest Comparative Effectiveness Public Advisory Council, issuing body.
- Publication:
-
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
- Language(s):
-
English
- Format:
-
Text
- Subject(s):
-
Amyloidosis, Familial -- drug therapy
RNA, Small Interfering -- therapeutic use
Amyloid Neuropathies, Familial -- drug therapy
Amyloidosis, Familial -- complications
Clinical Trials as Topic
Cost-Benefit Analysis
RNA, Small Interfering -- adverse effects
RNA, Small Interfering -- economics
Treatment Outcome
Humans
United States
- Genre(s):
-
Technical Report
- Copyright:
-
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
-
1 online resource (1 PDF file (various pagings))
- Illustrations:
-
Illustrations
- NLM Unique ID:
-
101745015 (See catalog record)
- Permanent Link:
-
http://resource.nlm.nih.gov/101745015
